Burroughs Wellcome Co.

Glaxo Wellcome Inc.

Other

Richard M Hyde

Malcolm Stuart Nobbs

Alistair A Miller

Michael John Leach

David J Livingstone

John Frederick Batchelor

Alistair Allen Miller

Michael J Leach

Malcolm S Nobbs

Williasm R King

Michael John

A class of substituted phenylpyrimidine compounds are disclosed which are potent inhibitors of the excitatory amino acid, glutamate. Such compounds are useful in the treatment or prevention of a range of CNS disorders including cerebral ischaemic damage and epilepsy.

2-(n-alkylpiperazino or morpholino)-4-amino-5-aryl-pyrimidines

Pharmacologically active CNS compounds

Certain 2,4-diamino-5-(2,3-dihalophenyl)-6-substituted pyrimidines which

Treatment of injury of the spinal cord or brain using

Treatment of damage from a stroke using

Certain 2,4-diamino-5-(2,3,5-TRI-chlorophenyl)-6-substituted-pyrimidines

Nitrile compounds

Tricyclic compounds of formula (I) ##STR1## wherein X.sup.1 is a carboxyl or 5-tetrazolyl group

Tetrazolyl substituted tricyclic compounds and pharmacological

Use of compounds of formula (I) ##STR1## to provide a more effective delivery of oxygen to the tissues of a mammalian, including human, recipient. In vivo applications include the relief or amelioration of conditions wherein there is tissue hypoxia; in vitro the compounds are of use in the storage of mammalian, including human, red blood cells to maintain their oxygen-delivery capacity and prolong their useful storage life. Also provided is a sterile, sealed vessel containing an anticoagulant, a non-toxic amount of a compound of formula (I) and optionally mammalian, in particular human, red blood cells.

Pharmacologically active ketones and use

Storage of red blood cells

Growing community of inventors

Beckenham, United Kingdom

Richard M Hyde